TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Autor: Haase, D, Stevenson, KE, Neuberg, D, Maciejewski, JP, Nazha, A, Sekeres, MA, Ebert, BL, Garcia-Manero, G, Haferlach, C, Haferlach, T, Kern, W, Ogawa, S, Nagata, Y, Yoshida, K, Graubert, TA, Walter, MJ, List, AF, Komrokji, RS, Padron, E, Sallman, D, Papaemmanuil, E, Campbell, PJ, Savona, MR, Seegmiller, A, Adès, L, Fenaux, P, Shih, L-Y, Bowen, D, Groves, MJ, Tauro, S, Fontenay, M, Kosmider, O, Bar-Natan, M, Steensma, D, Stone, R, Heuser, M, Thol, F, Cazzola, M, Malcovati, L, Karsan, A, Ganster, C, Hellström-Lindberg, E, Boultwood, J, Pellagatti, A, Santini, V, Quek, L, Vyas, P, Tüchler, H, Greenberg, PL, Bejar, R, Committee, International Working Group For Mds Molecular Prognostic

Publikováno v: Leukemia
Leukemia, vol 33, iss 7

Risk stratification is critical in the care of patients with myelodysplastic syndromes (MDS). Approximately 10% have a complex karyotype (CK), defined as more than two cytogenetic abnormalities, which is a highly adverse prognostic marker. However, C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d49797d5f17dd3791db8ac57149af6e
https://ora.ox.ac.uk/objects/uuid:e9f86a5f-8ced-4bb7-944f-fa27fc2c2541

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).

Autor: Aakash F; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Pathology, University of Texas Medical Branch, Galveston, Texas., Gisriel SD; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut; Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin., Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut., Bennett JM; James P. Wilmot Cancer Center, Division of Hematopathology, University of Rochester Medical Center, Rochester, New York., Bejar R; Division of Hematology and Oncology, Moores Cancer Center, UC San Diego, La Jolla, California., Bewersdorf JP; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York., Borate UM; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio., Boultwood J; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom., Brunner AM; Division of Hematology, Massachusetts General Hospital Brigham, Boston, Massachusetts., Buckstein R; Division of Medical Oncology/Hematology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada., Carraway HE; Leukemia Program, Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Churpek JE; Division of Haematology, Oncology, and Palliative Care, Department of Medicine, Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin., Daver NG; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas., DeZern AE; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland., Efficace F; Health Outcomes Research Unit, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy., Fenaux P; Service d'hématologie, Hôpital Saint-Louis (Assistance Publique Hôpitaux de Paris), Université de Paris-Cité, Paris, France., Figueroa ME; Biochemistry & Molecular Biology, Sylvester Comprehensive Cancer Center. University of Miami Miller School of Medicine, Miami, Florida., Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas., Gore SD; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland., Greenberg PL; Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, New York., Halene S; Section of Hematology, Department of Internal Medicine, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut., Hourigan CS; Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, District of Columbia., Kim TK; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Kim N; NCI, NIH, Bethesda, Maryland., Komrokji RS; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Kutchroo VK; Brigham and Women's Hospital, Boston, Massachusetts., List AF; Chief Scientific Officer, Stelexis Therapeutics, New York, New York., Little RF; Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, Maryland., Majeti R; Division of Hematology, Department of Medicine, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California., Nazha A; Department of Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Nimer SD; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Odenike O; Leukemia Program, Section of Hematology/Oncology, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, Illinois., Padron E; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota., Platzbecker U; Department of Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany., Della Porta MG; IRCCS Humanitas Research Hospital, Department of Biomedical Sciences, Humanitas University, Milan, Italy., Roboz GJ; Weill Cornell Medical College and New York Presbyterian Hospital, New York, New York., Sallman DA; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Santini V; Myelodysplastic Syndromes Unit, Department of Experimental and Clinical Medicine, Hematology, Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy., Sanz G; Health Research Institute La Fe, Valencia, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; CIBERONC, IS Carlos III, Madrid, Spain., Savona MR; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee., Sekeres MA; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Stahl M; Department of Medical Oncology, Division of Leukemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Starczynowski DT; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital, Cincinnati, Ohio., Steensma DP; David Steensma LLC, Cambridge, Massachusetts., Taylor J; Division of Hematology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Abdel-Wahab O; Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York., Wei AH; Department of Haematology, Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Victoria, Australia., Xie Z; Malignant Hematology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Xu ML; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut., Hasserjian RP; Department of Pathology, Massachusetts General Hospital Brigham, Boston, Massachusetts., Loghavi S; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: Sloghavi@mdanderson.org.

Publikováno v: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc [Mod Pathol] 2024 Dec; Vol. 37 (12), pp. 100615. Date of Electronic Publication: 2024 Sep 23.

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.

Autor: Komrokji RS; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Lanino L; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Ball S; Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN, USA., Bewersdorf JP; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Marchetti M; Azienda Ospedaliera Nazionale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Maggioni G; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Travaglino E; IRCCS Polilcinico San Matteo, Pavia, Italy., Al Ali NH; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Fenaux P; Saint Louis Hospital, Paris Cité University, Paris, France., Platzbecker U; University Hospital Leipzig, Leipzig, Germany., Santini V; University of Florence, Florence, Italy., Diez-Campelo M; Haematology Department, University Hospital Salamanca, Salamanca, Spain., Singh A; Cleveland Clinic, Cleveland, OH, USA., Jain AG; Cleveland Clinic, Cleveland, OH, USA., Aguirre LE; Dana Farber Cancer Institute, Boston, MA, USA., Tinsley-Vance SM; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Schwabkey ZI; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Chan O; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Xie Z; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Brunner AM; Dana Farber Cancer Institute, Boston, MA, USA., Kuykendall AT; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Bennett JM; University of Rochester Medical Center, Rochester, NY, USA., Buckstein R; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Bejar R; University of California San Diego, San Diego, CA, USA., Carraway HE; Cleveland Clinic, Cleveland, OH, USA., DeZern AE; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA., Griffiths EA; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Halene S; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Hasserjian RP; Massachusetts General Hospital, Boston, MA, USA., Lancet J; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., List AF; Precision BioSciences, Durham, NC, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Odenike O; Leukemia Program, University of Chicago Medicine and University of Chicago Comprehensive Cancer Center, Chicago, IL, USA., Padron E; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Patnaik MM; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA., Roboz GJ; New York-Presbyterian/Weill Cornell Medicine, New York, NY, USA., Stahl M; Dana Farber Cancer Institute, Boston, MA, USA., Sekeres MA; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Steensma DP; Ajax Therapeutics, Cambridge, MA, USA., Savona MR; Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN, USA., Taylor J; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Xu ML; Department of Pathology and Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA., Sweet K; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Sallman DA; Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Nimer SD; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Hourigan CS; Virginia Tech FBRI Cancer Research Center, Washington, DC, USA., Wei AH; Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia., Sauta E; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., D'Amico S; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Train, Milan, Italy., Asti G; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Castellani G; Department of Medical and Surgical Sciences-DIMEC, University of Bologna, Bologna, Italy., Delleani M; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Campagna A; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy., Borate UM; Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA., Sanz G; Instituto de Salud Carlos III, Valencia, Spain., Efficace F; Department of Haematology, La Fe University and Polytechnic Hospital, Valencia, Spain., Gore SD; Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA., Kim TK; Division of Hematology and Oncology, Vanderbilt Ingram Cancer Center and Vanderbilt University School of Medicine, Nashville, TN, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rozman M; Hospital Clínic Barcelona, Barcelona, Spain., Orfao A; Haematology Department, University Hospital Salamanca, Salamanca, Spain., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Foucar MK; University of New Mexico, Albuquerque, NM, USA., Germing U; Department of Haematology, Oncology, and Clinical Immunology, Heinrich Heine University, Düsseldorf, Germany., Haferlach T; MLL Munich Leukemia Laboratory, Munich, Germany., Scheinberg P; Beneficência Portuguesa de São Paulo Hospital, São Paulo, Brazil., Miyazaki Y; Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan., Iastrebner M; Sanatorio Sagrado Corazón, Buenos Aires, Argentina., Kulasekararaj A; King's College Hospital NHS Foundation Trust, NIHR/Wellcome King's Clinical Research Facility, London, UK., Cluzeau T; Nice University Hospital, Nice, France., Kordasti S; Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King's College, London, UK., van de Loosdrecht AA; Department of Hematology, Amsterdam University Medical Center, VU University Medical Center-Cancer Center, Amsterdam, Netherlands., Ades L; Saint Louis Hospital, Paris Cité University, Paris, France., Zeidan AM; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA., Della Porta MG; Center for Accelerating Leukemia/Lymphoma Research at Comprehensive Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: matteo.della_porta@hunimed.eu.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 Nov; Vol. 11 (11), pp. e862-e872. Date of Electronic Publication: 2024 Oct 09.